JOINN(SH:603127) Jin Rong Jie·2025-08-14 08:46Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index on August 14, highlighting the decline in both indices and providing insights into the pricing and premium of XD Zhaoyan New Drug Research Center Co., Ltd. in the A-share and H-share markets [1] Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. (stock code: 603127.SH/6127.HK) was established in 1995 and is a specialized contract research organization (CRO) focused on drug development services [1] - The company is headquartered in Beijing and has subsidiaries in multiple locations including Suzhou, Chongqing, Guangzhou, Wuxi, Wuzhou, Nanning, Yunnan, Shanghai, California, and Boston [1] - Zhaoyan New Drug has established a quality management system that complies with international standards and holds various certifications including CNAS/ILAC-MRA, NMPA (China), FDA (USA), PMDA (Japan), MFDS (Korea), OECD GLP, and AAALAC (animal welfare) [1] Market Performance - On August 14, the Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to close at 25519.32 points [1] - XD Zhaoyan New A-shares closed at 32.21 yuan, down 5.74%, and H-shares closed at 24.56 HKD, down 1.52% [1] - The A/H premium for XD Zhaoyan New reached 43.47%, ranking it 79th among AH shares, indicating that H-shares are relatively cheaper compared to A-shares [1]